The selective activation of prodrug (s) in tumor tissues by exogenous enzyme (s) for cancer
therapy can be accomplished by several ways, including gene-directed enzyme prodrug …

T cell receptor (TCR)-based adoptive T cell therapies (ACT) hold great promise for the
treatment of cancer, as TCRs can cover a broad range of target antigens. Here we …

Cell-based immunotherapy has become the new-generation cancer medicine, and" off-the-
shelf" cell products that can be manufactured at large scale and distributed readily to treat …

Background Procedures to prevent severe graft-versus-host disease (GVHD) delay immune
reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the …

The introduction of an inducible suicide gene such as the herpes simplex virus thymidine
kinase (HSV-TK) might allow exploitation of the antitumor activity of donor T cells after …

Administration of donor T cells expressing the herpes simplex–thymidine kinase (HS-tk) with
a hematopoietic stem cell (HSC) transplantation could allow, if graft-versus-host disease …

Addback of donor T cells following T cell-depleted stem cell transplantation (SCT) can
accelerate immune reconstitution and be effective against relapsed malignancy. After …

Gene therapy is a promising therapeutic strategy for genetic and acquired hematologic
diseases. With the improvements in gene transfer and expression, factors affecting safety …

BACKGROUND: Treatment of relapsed hematological malignancies after an allogeneic
peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) …

New technologies are needed to characterize the migration, survival, and function of antigen-
specific T cells in vivo. Here, we demonstrate that Epstein-Barr virus (EBV)–specific T cells …